PURPOSE: The purpose of this study was to show the effectiveness of combining intra-arterial infusion and systemic chemotherapy with concurrent radiotherapy for treatment of stage IV mandibular gingival cancer. MATERIALS AND METHODS: A total of 23 patients with mandibular gingival cancer were treated with either docetaxel by intra-arterial infusion followed by systemic chemoradiotherapy with cisplatinum and 5-fluorouracil as a monthly regimen, or with docetaxel and cisplatinum by intra-arterial infusion followed by systemic chemoradiotherapy with 5-fluorouracil as a weekly or biweekly regimen. Tumor responses, locoregional control, overall survival, disease-specific survival, and adverse events were evaluated. RESULTS: Of the 23 patients enrolled in the study, 22 completed the treatment. With regard to clinical stages, 82 % were diagnosed as IVA and 18 % IVB. Complete and partial response was observed in 82 and 18 %, respectively. Five-year overall survival, disease-specific survival, and locoregional control were 51, 70, and 72 %, respectively. No statistically significant difference was seen between the monthly regimen and the weekly plus biweekly regimen, although the latter resulted in longer survival and 88 % control. CONCLUSION: Combined intra-arterial infusion and systemic chemoradiotherapy may be an effective treatment for patients with stage IV mandibular gingival cancer.
PURPOSE: The purpose of this study was to show the effectiveness of combining intra-arterial infusion and systemic chemotherapy with concurrent radiotherapy for treatment of stage IV mandibular gingival cancer. MATERIALS AND METHODS: A total of 23 patients with mandibular gingival cancer were treated with either docetaxel by intra-arterial infusion followed by systemic chemoradiotherapy with cisplatinum and 5-fluorouracil as a monthly regimen, or with docetaxel and cisplatinum by intra-arterial infusion followed by systemic chemoradiotherapy with 5-fluorouracil as a weekly or biweekly regimen. Tumor responses, locoregional control, overall survival, disease-specific survival, and adverse events were evaluated. RESULTS: Of the 23 patients enrolled in the study, 22 completed the treatment. With regard to clinical stages, 82 % were diagnosed as IVA and 18 % IVB. Complete and partial response was observed in 82 and 18 %, respectively. Five-year overall survival, disease-specific survival, and locoregional control were 51, 70, and 72 %, respectively. No statistically significant difference was seen between the monthly regimen and the weekly plus biweekly regimen, although the latter resulted in longer survival and 88 % control. CONCLUSION: Combined intra-arterial infusion and systemic chemoradiotherapy may be an effective treatment for patients with stage IV mandibular gingival cancer.
Authors: Alexander D Rapidis; Miltiades Trichas; Elias Stavrinidis; Alexandra Roupakia; Georgia Ioannidou; George Kritselis; Panaiyota Liossi; George Giannakouras; Emmanuel E Douzinas; Ioannis Katsilieris Journal: Oral Oncol Date: 2006-05-30 Impact factor: 5.337
Authors: Marshall R Posner; Robert I Haddad; Lori Wirth; Charles M Norris; Laura A Goguen; Anand Mahadevan; Christopher Sullivan; Roy B Tishler Journal: Semin Oncol Date: 2004-12 Impact factor: 4.929
Authors: Joshua Lubek; Michel El-Hakim; Andrew R Salama; Xinggang Liu; Robert A Ord Journal: Br J Oral Maxillofac Surg Date: 2010-05-11 Impact factor: 1.651
Authors: K T Robbins; P Kumar; F S Wong; W F Hartsell; P Flick; R Palmer; A B Weir; H B Neill; T Murry; R Ferguson; C Hanchett; F Vieira; A Bush; S B Howell Journal: Head Neck Date: 2000-10 Impact factor: 3.147
Authors: Y Korogi; T Hirai; R Nishimura; S Hamatake; Y Sakamoto; R Murakami; Y Baba; A Arakawa; M Takahashi; Y Uji Journal: AJR Am J Roentgenol Date: 1995-11 Impact factor: 3.959